HYBRID MOLECULE OF FORMULA GM-CSF-L-EPO OR EPO-L-GM-CSF FOR HEMATOPOIETIC STIMULATION

Abstract: It is described a hybrid molecule of formula GM-CSF-L-EPO or EPO-L-GM-CSF useful for the stimulation of hematopoiesis, comprising GM-CSF and EPO molecules fused together by means of a linker L having a variable length of amino acids, GM-CSF and EPO molecules being either complete molecules or fragments thereof. Such hybrid molecules exhibit a higher specificity of action on erythroid differentiation if compared to that of an equimolar mixture of not-linked GM-CSF and EPO molecules. Further, the present invention describes: DNA sequences encoding such hybrid molecules, which stimulate the hematopoiesis; plasmid vectors containing the genes encoding hybrid molecules and directing their synthesis in host cells; the use of such hybrid molecules for the preparation of a pharmaceutical composition and such pharmaceutical composition useful for stimulation of hematopoiesis.

Description: Hybrid molecule of formula GM-CSF-L-EPO or EPO-L-GM-CSF for hematopietic stimulation Field of the invention The present invention relates to hybrid hematopoietic factors for the stimulation of hematopoiesis. In particular, to hybrid molecules of formula GM-CSF-L-EPO or EPO-L-GM-CSF comprising complete GM-CSF and EPO molecules or fragments thereof fused by means of a linker L having a variable length of amino acids. Such hybrid molecules exhibit a higher specificity of action on erythroid differentiation if compared to that of an equimolar mixture of not-linked GM-CSF and EPO molecules. State of the art Hematopoiesis is a multi-step cell proliferation and differentiation process starting from a pool of multipotent stem cells. These cells can proliferate and differenziate into hematopoietic progenitors in reply to different stimuli. A group of proteins named growth factors or Colony Stimulating Factors (CSFs) or cytokines control survival, proliferation and differentiation of stem and progenitor cells. Furthermore, they affect several functional activities of mature terminal cells. In brief, at the level of immature cells, CSFs assure the self-renewal of the staminal pool and activate the first stage of hematopoietic differentiation; in the middle stage, when cell proliferation is associated to a progressive acquisition of characteristics of mature cells, they enormously enhance the number of differentiating cells; in the terminal stage they control the circulation and the activation of mature cells. For many CSFs, the target cell is known. Interleukin 3 (IL3) acts on multipotent (CFU-GEMM) , myeloid (CFU-GM) , erythroid (BFU-E) and megakaryocytic (CFU-MK) progenitors, whereas GM-CSF exerts its effects on early progenitors. Erythropoietin (EPO), G-CSF, interleukin 5 (IL5) and M-CSF are specific for end-stage progenitors of the erythroid (CFU-E) , granulocytic (CFU-G) , eosinor.hilic (CFU-Eo) and monocytic (CFU-M) lineage, respectively. The importance of these molecules is justified by their potential clinical use. In particular, the EPO administration, which causes an increase of blood cells, is useful in case of anaemia, aplasia or marrow hypoplasia induced by chemotherapy or radiant theraphy and in hemodialysed patients with chronic renal failure. The administration of GM-CSF, as shown by some preliminary clinical studies, is useful when the organism absolutely needs to produce granulocytes, for example under AIDS conditions or during anti-blastic theraphy in case of neoplasia or transplantation. The interaction of several growth factors at the level of single cells can have sinergetic or antagonist additive effects. For example, severe anemia responds well to the combination of GM-CSF and IL3 with EPO (Clark S.C., Kamen R. , 1987, Science, 236:1229). Since current blood available is not sufficient for covering transfusion needs and as the risk of haematic contact diseases like AIDS, B and C hepatitis, etc. is higher and higher, it is justified the industrial interest for the production of recombinant hematopoietic factors or new molecules with hemopoietic activity. Patent application 092/06116 discloses recombinant hematopoietic hybrid growth factors comprising an early factor and a late factor. As early factors are disclosed IL-3 and GM-CSF, whilst as late factors it discloses EPO, G-CSF, IL5 and M-CSF. Said patent application describes only hybrid growth factors IL3:EP0, EP0:IL3 and IL3:G-CSF, wherein the two components of each hybrid factor can be fused together directly or by means of a linker. Although said patent application also quotes the GM-CSF molecule (pag.7) • no description or indication is given with reference to the behaviour and use of said molecule in combination with EPO. The authors of patent application WO 92/06116 assume that the early factor (IL3) down-regulates the expression of the receptors for the late fator (EPO) and therefore it leads to decrease the receptors for the late factor. On the other hand, Testa U. , et al. (Blood, 8l, 14-42-1456, 1993) found that the early factor acts positively up-stimulating the expression of receptors for late factors. Therefore, one come to the conclusion that the effects induced by early/late factors have not been understood yet. Further, the authors of said patent application have disclosed data on the biological activity of the hybrid factor IL3:EP0 or EP0:IL3 (clonogenic test; Table IV) showing that said hybrid molecules stimulate BFU-E and CFU-E colonies of bone marrow cells. As they did not report data on the induction of CFU-GM colonies, it was not possible to foresee or argue a specificity of action on the erythroid differentiation by means of said hybrid factors. Moreover, said Table IV did not show substantial differences between the effect of the IL3:EP0 or EP0:IL3 hybrid factors on the production of erythroid cells (BFU-E and CFU-E cells) and the effect exerted by IL3 + EPO mixture. Furthermore, the clonogenic test reported in said application was performed with not-purified progenitor cells of bone marrow; it is therefore possible that the final observation was conditionated by the presence of contaminants or secondary cells (that is cells secreting endogenous growth factors; Peschle C. et al., 1993. Stem Cell, 11, 356- 370). In short, in the light of publications cited, we can consider that the date disclosed in WO 92/06116 are at present hardly interpretable. Summary of the invention The authors of the present invention found that the new hybrid molecules of formula GM-CSF-L-EPO or EPO-L-GM-CSF comprising complete GM-CSF and EPO molecules or fragments thereof fused by means of a linker L having a variable length of amino acids surprisingly exhibit a higher specificity of action on erythroid differentiation if compared to that of an equimolar mixture of not-linked GM-CSF and EPO molecules. It was not possible to assume or foresee this result on the basis of the state of the art. Furthermore, the present invention relates to a nucleotide sequence encoding said fused molecule, to an expression vector comprising said nucleotide sequence and to a cell host comprising said vector. The present invention also relates to the use of said fused molecules for the preparation of a pharmaceutical composition and to said pharmaceutical composition useful for the stimulation of hematopoiesis. Brief description of Figures and Sequences - Figure 1 shows the structural scheme referring to hybrid molecules GM- CSF-Ll-( \ 1-4)EPO, GM-CSF-L2-(Δ 1-4)EPO and EP0-L3-GM-CSF wherein LI and L3 are the linkers of a sequence of 16 amino acids whilst L2 is a linker of 8 amino acids. The sign ( 1-4)EPO indicates that the EPO molecule lacks the first four amino acids. - Figure 2 shows the construction of the hybrid gene encoding the fusion hybrid protein GM-CSF-L1-( 1-4)EPO. - Figure 3 shows the riduction of linker LI (l6aa) to L2 (8aa) by means of restriction endonuclease digestion of DNA with Nael. - Figure 4 shows the construction of the hybrid gene encoding the fusion hybrid protein EP0-L3-GM-CSF. - Figure 5 shows a histogram wherein the concentration of growth factors added to the culture are expressed in ng/ml is reported in the abscissas, whereas the axis of ordinates reports the number of erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) colonies induced by the mixture of the two growth factors GM-CSF and EPO (Standard) or by the hybrid molecules LI and L2. - SEQ ID N0:1 reports the sequence of oligonucleotide of 105 bases. -SEQ ID NO:2 reports the nucleotide sequence of 48 bases encoding the linker LI. - SEQ ID NO:3 reports the sequence of 16 amino acids of the linker LI. - SEQ ID NO:4 reports the nucleotide sequence of the hybrid molecule GM- CSF-L1-(Δ 1-4)EPO. - SEQ ID NO:5 reports the nucleotide sequence of 24 bases encoding the linker L2. - SEQ ID NO:6 reports the sequence of 8 amino acids of the linker L2. - SEQ ID NO:7 reports the nucleotide sequence of the hybrid molecule GM- CSF^-(Λ.1-4)EPO. - SEQ ID NO:8 reports the nucleotide sequence of 48 bases encoding the linker L3- - SEQ ID NO:9 reports the sequence of 16 amino acids of the linker L3- - SEQ ID NO:10 reports the nucleotide sequence of an oligonucleotide of 36 bases . - SEQ ID NO:11 reports the nucleotide sequences of an oligonucleotide of 57 bases. -SEQ ID NO:12 reports the nucleotide sequence of the hybrid molecule EPO- L3-GM-CSF. Detailed description of the invention According to the present invention, authors obtained many hybrid molecules by means of fusion of genie fragments encoding GM-CSF, linker and EPO, and their expression in host cells. Host cells were selected from the group consisting of bacterial, yeast, insect, plant or mammalian cells. The use of CHO cells is preferable. The hybrid molecules according to the invention are indicated by the formula GM-CSF-L-EPO or EPO-L-GM-CSF, wherein said hybrid molecule is constituted by complete molecules of GM-CSF (127 amino acids) and EPO (166 amino acids) or by fragments thereof fused by means of a linker L having a variable length of amino acids. The construction of hybrid genes encoding the proteins according to the invention is as follows. I) A sequence of DNA encoding the fusion protein comprising the GM-CSF at the N-terminus, a linker and the EPO at the C-terminus, that is comprising from 5' to 3' the following portions: a) the untranslated 5' region of cDNA of GM-CSF; b) the GM-CSF encoding sequence; c) an oligonucleotide encoding a linker peptide; d) the EPO encoding sequence; e) the untranslated region of EPO. II) A sequence of DNA encoding the fusion protein comprising the EPO at the N-terminus, a linker and the GM-CSF at the C-terminus, that is comprising from ' to 3' the following portions: a) the untranslated 5' region of cDNA of EPO; b) the EPO encoding sequence; c) an oligonucleotide encoding a linker peptide; d) the GM-CSF encoding sequence; e) the untranslated region of GM-CSF. According to a preferred embodiment of the invention, the hybrid molecules obtained are the following: GM-CSF-Ll-(^ 1-4)EPO (also named MEN 11301), GM-CSF-L2-(A 1-*4)EP0 (also named MEN 11300) and EP0-L3-GM-CSF (also named MEN 11303). wherein LI and L3 refer to a linker of 16 amino acids of length, whilst L2 refers to a linker of 8 amino acids of length. The term (/ 1-4)EPO means that the EPO molecule lacks the first four amino acids and it is also indicated as 5-166 amino acids (5-I66 aa) of EPO. The structural schemes according to the above molecules are shown in Figure 1. According to this embodiment, the above hybrid genes were cloned in expression vectors according to the patent application PCT/EP 94/03488 and transfected in CHO cells. The recombinant hybrid cells expressed in CHO cells were functionally studied by a clonogenic test on human purified stem cells. The obtained functional data show that the three hybrid molecules, released in the media by transfectants, induce erythroid differentiation. Surprisingly, the ratio of the number of erythroid colonies and granulocyte-macrophage colonies in cultures treated with the hybrid molecules of the invention is higher than in the cultures treated with the mixture of the two factors GM-CSF and EPO, indicating a functional advantage in the selective induction of the erythroid differentiation of the molecules fused in a single polipeptide chain if compared to the mixture (Table 1). Some specific embodiments according to the present invention are hereinafter described in the following examples. Example 1 Construction of the hybrid gene encoding the fusion protein GM-CSF-L1-(A 1-4)EPO The hybrid gene encoding the fusion protein comprising GM-CSF at the N- terminus, the linker LI and EPO at the C-terminus, was obtained as follows. A) The EPO cDNA inserted in pGEM7Z (5' SmaI-3'EcoRI) (Promega Biotec, Madison, WI, USA) was cloned in the Kpnl-EcoRI sites of the pGEM4Z vector (Promega Biotec, Madison, WI, USA). The restriction with Kpnl implies the elimination of the first 17 amino acids of the protein; amino acids from +5 to +17 were then restored by means of the fusion with the linker sequence, as better specified in B) . B) The cDNA portion of GM-CSF used for the construction of the fusion protein was obtained by means of PCR using as template the cDNA of the GM-CSF cloned in pGEM7Z (5'EcoRI-3'Hindlll) and as 5' primer the oligonucleotide corresponding to the T7 promoter of the pGEM7Z vector (Promega Biotec, adison, WI, USA) and as 3' primer the oligonucleotide of 105 bases, whose sequence is reported in SEQ ID N0:1 having 18 bases complementary to the 3' coding region of GM-CSF (with exclusion of the stop codon) , 48 bases (whose sequence is reported in SEQ ID NO:2 and in Figure 3) encoding a molecular linker whose sequence is a modified version of the linker described by Huston et al., (PNAS, 1988, USA, 85.5879-5883) and 39 bases encoding the amino acids from position +5 to position +17 of EPO. The PCR product was cleaved at Xbal-Kpnl. This digestion implies the elimination at 3' of the last 6 nucleotides encoding amino acids +16 and +17 of EPO, already present in the EPO sequence cloned in pGEM4Z-EP0. The digested amplified product was cloned in the same sites of the pGEM4Z-EP0 above described, restoring the EPO amino acids at position from +5 to +15. The pGEM4Z-GM-CSF-Ll-EP0 was digested with Sall/Bglll and the fragment cloned in pGEMHZ (Promega Biotec) in the sites Sail e BamHI and therefore in the final vector pMCMVfJSVlDHFR (already described in patent application PCT/EP 94/03488), cloning in the Xbal site (Figure 2). The nucleotide sequence encoding the hybrid molecule GM-CSF-Ll-( / 1" 4)EPO determined with the method of Sanger (SEQUENASE Version 2.0 DNA Sequencing kit. UNITED STATES BIOCHEMICAL) is reported in SEQ ID NO:4. The amino acid sequence of the mature hybrid protein GM-CSF-L1-( 1" 4)EPO comprises: a) 127 amino acids of GM-CSF; b) linker peptide of 16 amino acids having the sequence: AlaGlyGlyGlyGlySerGlyGlyAlaGlySerGlyGlyGlyGlySer (SEQ ID NO:3 and Figure 3); c) 162 amino acids of EPO. Example 2 Construction of the hybrid gene encoding the fusion protein GM-CSF-L2-(Λ 1-4)EPO The hybrid gene encoding the fusion protein comprising GM-CSF at the N- terminus, the linker L2 (24 bases reported in SEQ ID NO: and in Figure 3) and EPO at the C-terminus, was obtained as follows. A) The pGEM4Z-GM-CSF-Ll-EP0 construct was digested with the restriction enzyme Nael. This enzyme has two restriction sites in the linker LI. The digestion with Nael eliminates 24 bases of the linker LI leaving, between GM-CSF and EPO, the amino acid sequence AlaGlySerGlyGlyGlyGlySer (SEQ ID NO:6 and Figure 3) • Subcloning steps for transferring GM-CSF-L2-(Λ_ 1-4)EPO from pGEM4Z to pMCMVβSVlDHFR are analogous to those described for GM-CSF-L1-( 1-4)EPO (Figure 2) . The nucleotide sequence encoding the hybrid molecule GM-CSF-L2-(A 1- 4)EPO determined with the method of Sanger (SEQUENASE Version 2.0 DNA Sequencing kit. UNITED STATES BIOCHEMICAL) is reported in SEQ ID N0:7- The amino acid sequence of the mature hybrid protein GM-CSF-L2-(/\ 1- 4)EPO comprises: a) 127 amino acids of GM-CSF; b) a linker peptide of 8 amino acids having the sequence AlaGlySerGlyGlyGlyGlySer (SEQ ID NO:6); c) 162 amino acids of EPO. Example 3 Construction of the hybrid gene encoding the fusion protein EP0-L3-GM-CSF The cDNA encoding the fusion protein comprising EPO at the N-terminus, the linker L3 (a sequence of 16 amino acids reported in SEQ ID NO:9) and GM-CSF at the C-terminus, was prepared as follows. A) EPO cDNA was amplified using as template pGEM7Z-EP0 after EcoRI restriction emzyme digestion, as 5' primer the oligonucleotide corresponding to the SP6 promoter (Promega, Biotec, Madison, WI, USA) and as 3' primer an oligonucleotide of 36 bases (SEQ ID N0:10), wherein 12 bases were complementary to the 3' of the template (excluding the stop codon) and 24 bases encoded the 5' portion of the linker L3; B) GM-CSF cDNA was amplified using as template pGEM7Z-GM-CSF after EcoRI restriction enzyme digestion, as 3' primer the SP6 and as 5' primer an oligonucleotide of 7 bases (SEQ ID NO: 11), wherein 42 bases encoded the 3 1 portion of the linker L3 and 15 bases were complementary to the sequence encoding the first 5 amino acids of the mature protein. The complete nucleotide sequence of linker L3 is reported in SEQ ID NO:8. The products of the two PCRs, digested respectively with Sacl/Aval and Aval/BamHI enzymes, were cloned in pGEM4Z in the restriction sites SacI/BamHI. The pGEM4Z-EPO-L3-GM-CSF was digested at Clal/BspHI and, after filling in ends to have them blunt by means of the KLENOW polymerase (BOEHRINGER MANNHEIM) , the fragment was cloned in the Smal site of pMCMVβSVlDHFR (Figure 4). The nucleotide sequence encoding the hybrid molecule EP0-L3-GM-CSF determined with the method of Sanger (as above) is reported in SEQ ID N0:12. The amino acid sequence of the mature hybrid protein EP0-L3-GM-CSF comprises: a) 166 amino acids of EPO; b) the linker peptide of 16 amino acids having the sequence: AlaGlyGlyGlyGlySerGlyGlyGlyGlySerGlyGlyAlaGlySer (SEQ ID N0:9); c) 127 amino acids of GM-CSF. Preparation of the cell lines producing the recombinant hybrid molecules GM-CSF-L1-(A 1-4)EP0, GM-CSF-L2- 1-4)EP0 and EP0-L3-GM-CSF The mammalian cells used for the expression of the recombinant hybrid molecules are CHOdhfr " (CHO DUKXBl) (Urlaub G., Chaisin L.A. , 1980, Proc. Natl. Acad. Sci. 77:4216). The cells were transfected using the LIPOFECTIN produced by GIBCO BRL (Feigner P.L., Holm M. , 1989, Focus, 11-2:21). The clones, selected after transfection, were subjected to amplification cicles upon increasing concentrations of methotrexate (SIGMA) . Determination of the expression levels The fusion proteins were assayed in the conditioned medium by two ELISA tests: i) EPO ELISA (BOEHRINGER MANNHEIM); ii) GM-CSF ELISA (AMERSHAM) . Biological characterization The evaluation of the biological activity of the hybrid proteins produced in the conditioned media was obtained by clonogenic test on human stem cells as known in the state of the art (Valtieri M. , et al., 1989, Blood, 74:460). The results show that the GM-CSF and EPO factors linked as a single hybrid polypeptide chain induce, in the human stem cell cultures, a higher number of erythroid colonies and a lower number of granulocyte- macrophage colonies than the colonies treated with equimolar amounts of the mixture of the two factors not-linked (Figure 5) • These data show a higher specifity of action on the erythroid differentiation of the hybrid molecules compared to the same molecules not-linked. Table 1 shows that the ratio between the number of erythroid and granulocyte-macrophage colonies results higher in the cultures treated with the hybrid molecules than in the cultures treated with equimolar amount of the two not-linked factors (GM-CSF and EPO Standard from Genetic Institute and Amgen, respectively) . This fact was independent from the assayed concentrations (Table 1). Further, another characteristic of the present invention is a process for the production of the hybrid protein according to the invention, comprising the cultivation of the host cell above described, according to the methods known in the art, under suitable conditions for the expression of the DNA sequence and the recovery of the protein from the culture. Another characteristic of the present invention is also a pharmaceutical composition comprising the hybrid protein according to the invention, in combination with pharmaceutically suitable carriers or excipients. Furthermore, the present invention also refers to the use of the hybrid protein according to the invention, for the preparation of a pharmaceutical composition useful for the erythropoiesis stimulation. Table 1 BFU-E/CFU-GM Amount GM-CSF + EPO LI* L2** L3** (ng/ml) 0.14 1.4 3.0 2.25 1.4 1.4 4.6 9-0 6.7 5.0 7.0 7-2 10.0 11.6 8.0 * GM-CSF-Ll-(_ 1-4)EPO ** GM-CSF-L2-(_ 1-4)EPO *** EP0-L3-GM-CSF

Claims: Claims 1. A hybrid protein, useful for the stimulation of hematopoiesis, having the formula GM-CSF-L-EPO or EPO-L-GM-CSF, wherein L is a linker having a variable length of amino acids and wherein the GM-CSF and EPO molecules are complete molecules or fragments thereof. 2. A hybrid protein according to claim 1, comprising from 5' to 3' the following components: a) amino acids 1-127 of GM-CSF; b) a linker; c) amino acids 5-166 of EPO. 3• A hybrid protein according to claim 1, comprising from 5' to 3' the following components: a) amino acids 1-166 of EPO; b) a linker; c) amino acids 1-127 of GM-CSF. 4. A hybrid protein according to claims 2-3, wherein said linker is a sequence of 16 amino acids. 5- A hybrid protein according to claim 4, wherein said linker is the sequence of SEQ ID NO:3 or the sequence of SEQ ID NO:9. 6. A hybrid protein according to claims 2-3, wherein said linker is a sequence of 8 amino acids. 7- A hybrid protein according to claim 6, wherein said linker is the sequence of SEQ ID NO:6. 8. A DNA sequence encoding a hybrid protein according to claim 1. 9- A DNA sequence according to claim 8, comprising from 5' to 3' the following components: a) the untranslated 5' region of the cDNA of GM-CSF; b) the GM-CSF encoding sequence; c) an oligonucleotide; d) the EPO encoding sequence; e) the untranslated 3' region of EPO. 10. A DNA sequence according to claim 8, comprising from 5' to 3' the following components: a) the untranslated 5' region of the cDNA of EPO; b) the EPO encoding sequence; c) an oligonucleotide; d) the GM-CSF encoding sequence; e) the untranslated 3' region of GM-CSF. 11. A DNA sequence according to claims 9 _ 10, wherein said oligonucleotide is a sequence of 48 nucleotides. 12. A DNA sequence according to claim 11, wherein said oligonucleotide has the sequence of SEQ ID NO:2. 13. A DNA sequence according to claim 11, wherein said oligonucleotide has the sequence of SEQ ID N0:8. 14. A DNA sequence according to claims 9~10, wherein said oligonucleotide is a sequence of 24 nucleotides. 15. A DNA sequence according to claim 14, wherein said oligonucleotide has the sequence of SEQ ID N0:5. 16. A recombinant expression vector comprising a DNA sequence according to claim 8. 17. A host cell genetically modified with the vector according to claim 16, characterized by the fact that said host is a bacterial, a yeast, an insect, a plant or a mammalian cell. 18. A process for the production of hybrid protein according to claim 1, comprising the cultivation of the host cell of claim 17 under suitable conditions for the expression of the DNA sequence and the recovery of the protein from the culture. 19- A pharmaceutical composition comprising a hybrid protein according to claim 1, in combination with suitable carriers or excipients. 20. Use of a hybrid protein protein according to claim 1, for the preparation of a pharmaceutical composition useful for hematopoiesis stimulation.

Inventors: CARLONI CRISTINA, COSCARELLA ANNAMARIA, DE SANTIS RITA, MELE ANTONIO, CARLONI, CRISTINA, COSCARELLA, ANNAMARIA, DE SANTIS, RITA, MELE, ANTONIO
Applicants: CARLONI CRISTINA, COSCARELLA ANNAMARIA, MELE ANTONIO, MENARINI RICERCHE SUD SPA, SANTIS RITA DE, CARLONI, CRISTINA, COSCARELLA, ANNAMARIA, DE SANTIS, RITA, MELE, ANTONIO, MENARINI RICERCHE SUD S.P.A.
Application year: 1995
Main classification: C12N15
IPC codes: A61K38, A61P7, C07H21, C07K14, C07K19, C12N1, C12N5, C12N15, C12P21